• Medistim posted Q2 revenue up 19.5% to NOK 202 million, setting a first-half record with revenue up 15.1% to NOK 403.7 million.
• Q2 operating profit (EBIT) rose 20.6% to NOK 65.3 million, leaving the EBIT margin at 32.3%.
• First-half EBIT climbed 8% to a record NOK 122.4 million, while the EBIT margin narrowed 2 percentage points to 30.3%.
• Recurring sales share held at 67% in the first half, broadly steady versus 66.8% a year earlier.
• Japan direct sales operation launched March 16, 2026; quarter-end cash was NOK 100.2 million with no interest-bearing bank loans.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medistim ASA published the original content used to generate this news brief on August 21, 2026, and is solely responsible for the information contained therein.